The Scientific Advisory Board (SAB) at Bay Area Lyme Foundation provides strategic guidance and oversight for our research and scientific programs. These leaders represent some of the most important researchers and clinical innovators in the field of Lyme disease who have all made important contributions to the understanding, diagnosis, and treatment of the disease.

John N. Aucott, MD, Johns Hopkins University School of Medicine

Charles Chiu, MD, PhD, University of California, San Francisco

Monica Embers, PhD, Tulane University Health Sciences

Christine Green, MD, Board Member, & ILADS

Robert S. Lane, PhD, University of California, Berkeley

William Robinson, MD, PhD, Stanford University School of Medicine

Neil Spector, MD, Duke University School of Medicine

Irving Weissman, MD, Stanford University School of Medicine


Dr. John AucottJohn N. Aucott, MD

Assistant Professor, Johns Hopkins School of Medicine; Founder, Lyme Disease Research Association

Dr. Aucott is a renowned expert in clinical research on the diagnosis and epidemiology of Lyme disease. He is the founder and president of Lyme Disease Research Foundation, a public nonprofit organization founded to promote research and education in Lyme disease. Dr. Aucott was a Principal Investigator with Dr. Mark Soloski, for the landmark SLICE (Study of Lyme Disease Immunology and Clinical Events) project, a prospective cohort study examining the impact of acute Lyme disease on long-term health outcomes and immune function. Dr. Aucott is a practicing clinician at Park Medical Associates and part of the teaching faculty at Johns Hopkins School of Medicine where his focus has been on clinical translation research in Lyme disease.

Charles ChiuCharles Chiu, MD, PhD

Assist. Professor, UCSF (Laboratory Medicine & Infectious Diseases); Director, UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC); Associate Director, UCSF Clinical Microbiology Laboratory

Dr. Chiu is an expert in the development and implementation of advanced genomic technologies for pathogen discovery and clinical diagnostics, including microarrays and next-generation sequencing, for a variety of blood-borne infections. His efforts in Lyme disease focus on the development of diagnostics for both pathogen detection and host response. He uses next-generation sequencing and has developed the “TickChip” to directly detect the RNA of Lyme bacteria and other tick-borne pathogens.  He is also using RNA-sequencing technology to detect and identify a diagnostic profile of the body’s response to being infected by Lyme disease. He recently published in the highly prestigious New England Journal of Medicine, as described in a New York Times article, about the ability to uniquely and expeditiously diagnose a disease caused by a bacteria that is in the same family as Lyme disease.

scientists_Monica EmbersMonica E. Embers, PhD

Assistant Professor, Tulane University Health Sciences (Bacteriology and Parasitology)

Dr. Embers’ research program regarding Borrelia burgdorferi and Lyme disease is designed around two major foci: (1) antibiotic efficacy against Lyme disease; and (2) immunodiagnosis for B. burgdorferi infection and cure. The first research goal is to examine, using xenodiagnosis, the efficacy of antibiotic treatment during disseminated B. burgdorferi infection.  The second goal is to develop a quantitative multi-antigen test that expands detection limits and helps to distinguish persistent infection from clinical cure.  By studying the natural course of infection, her group hopes to facilitate a better understanding of the clinical quandaries of human Lyme disease, including effective diagnosis and treatment.

christine green_156Christine Green, MD

Director of Education for International Lyme and Associated Diseases Society; Board Member, International Lyme and Associated Disease Society (ILADS) and (formerly CALDA)

Dr. Green is a recognized leader in Lyme disease diagnosis and treatment who practices complementary, integrative, and othomolecular medicine from her private family practice, Green Oaks Medical, in northern California.  She serves on the board of ILADS (International Lyme and Associated Diseases Society) and and has helped to bring greater awareness to the medical community through patient research and advocacy. She currently serves as the Director of Education for ILADS. Dr. Green has a true passion for her profession and patients, demonstrated by her commitment to constant collaboration and ongoing research within the patient and medical community and she possesses a unique ability to problem solve patient issues, seeking out unconventional uses of therapy, based on Western Medicine research and clinical studies.

Robert S. Lane, PhD

Professor, University of California, Berkeley (Environmental Science, Policy & Management)

Dr. Lane, a professor of Environmental Science, Policy and Management at University of California, Berkeley, studies the ecology and epidemiology of Lyme disease with a focus on the transmission cycles of the Lyme-causing spirochete and other emerging bacterial disease agents. This work has yielded the identification of several new species of spirochetes not previously documented in North America and clarified the role of over 50 bird species in the ecology of Lyme bacteria in the far Western US. Dr. Lane has also developed predictive models to assess county and state level variations in Lyme disease risk and is working on environmentally safe pesticides that target rodent reservoir hosts. Dr. Lane is a fellow of the California Academy of Sciences and the American Association for the Advancement of Science.

William RobinsonWilliam Robinson, MD, PhD

Assoc. Professor, Stanford University Dept. of Medicine (Immunology & Rheumatology)

Dr. Robinson is a board certified rheumatologist on the teaching faculty at Stanford’s School of Medicine and has clinical practices affiliated with Stanford Hospital and the VA Hospital in Palo Alto. He is also a member of the Stanford Lyme Working Group (SLWG). His laboratory studies the molecular mechanisms of autoimmune and rheumatic diseases, and develops therapies to treat rheumatoid arthritis, multiple sclerosis, and osteoarthritis. The lab is a part of the Division of Immunology and Rheumatology in the Department of Medicine, the Program in Immunology, and the Center for Clinical Immunology at Stanford (CCIS) at Stanford University School of Medicine. It is also part of the Institute for Immunity Transplantation and Infection (ITI) at Stanford.

Neil Spector_156Neil Spector, MD

Associate Professor of Medicine, Duke University; Sandra Coates Associate Professor; Associate Professor of Pharmacology & Cancer Biology; Member of the Duke Cancer Institute

Neil Spector, MD is the Sandra P. Coates chair in breast cancer research and an associate professor of medicine as well as pharmacology and cancer at Duke University School of MedicineHe co-directs the experimental therapeutics program for the Duke Cancer Instituteand is a Komen scholar.  His book: Gone in a Heartbeat, a Physicians Search for True Healing was inspired by his personal story with Lyme disease.


irv weissman_156Irving Weissman, MD

Professor, Stanford University (Developmental Biology & Cancer Research); Director, Stanford Institute of Stem Cell Biology and Regenerative Medicine; Director, Ludwig Center for Cancer Stem Cell Research at Stanford University

Dr. Weissman is a Professor of Pathology and Developmental Biology at Stanford and the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine and the Ludwig Center for Cancer Stem Cell Research. His research encompasses the phylogeny and developmental biology of the cells that make up the blood-forming and immune systems and he was the first to discover and isolate the mammalian and hematopoietic (or blood-forming) stem cells.  He is also a leading expert in the field of cancer stem cell biology, pioneering the the study of genes and proteins involved in cell adhesion events (both as normal function and as events involved in malignant leukemic metastases). This work highlights the role of phagocytic cells such as macrophages with important implications for the development of new therapies, including a cancer treatment current in development that enlists the immune system to help attack persistent residual malignancies that linger and hide after traditional treatments.